# Atea Pharmaceuticals, Inc.: overview AVIR · Nasdaq · CIK 1593899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/avir.md) · [Financials](/companies/avir/financials.md) · [Filings](/companies/avir/filings.md) · [Insiders](/companies/avir/insiders.md) Latest reported revenue: [$192.2m](/filings/0000950170-23-005186.md) for Q4 FY2021, three months to 2021-12-31, from the 10-K filed Feb 28, 2023 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-23-005186). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.37)](/filings/0001193125-25-277815.md) | not reported | [(0.40)](/filings/0001193125-26-219678.md) | [(0.44)](/filings/0001193125-26-347021.md) | [(0.53)](/filings/0001193125-25-277815.md) | not reported | [(0.57)](/filings/0001193125-26-219678.md) | [(0.41)](/filings/0001193125-26-347021.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [351](/filings/0000950170-23-005186.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [39.4%](/filings/0000950170-23-005186.md) | not reported | not reported | not reported | not reported | | Net margin | % | [34.5%](/filings/0000950170-23-005186.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [1.37](/filings/0000950170-23-005186.md) | [(1.39)](/filings/0000950170-24-022226.md) | [(1.63)](/filings/0000950170-25-034808.md) | [(2.00)](/filings/0001193125-26-094159.md) | [(1.94)](/filings/0001193125-26-094159.md) | | Free cash flow | $m | [(87.0)](/filings/0000950170-23-005186.md) | [(123)](/filings/0000950170-24-022226.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avir/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $55.8m | 12,004,064 | | Added +53,292 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $40.5m | 8,720,077 | | Added +284,640 | | [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $32.3m | 6,952,330 | | Reduced −106,327 | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $22.4m | 4,814,700 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.8m | 2,964,862 | | Reduced −281,262 | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $9.7m | 2,075,639 | | Reduced −284,999 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $9.1m | 1,958,435 | | Added +210,729 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $7.7m | 1,652,399 | | Reduced −42,236 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $7.0m | 1,506,697 | | Reduced −357,467 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $6.0m | 1,299,515 | | Added +44,031 | ## Recent filings [All 312 filings](/companies/avir/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 20:45 ET | [10-Q](/filings/0001193125-26-347021.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347021 | | 2026-08-12 | 20:15 ET | [8-K](/filings/0001193125-26-346888.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346888 | | 2026-06-22 | 20:53 ET | [8-K](/filings/0001193125-26-277639.md) | 5.07 Shareholder vote results | 0001193125-26-277639 | | 2026-05-12 | 20:45 ET | [10-Q](/filings/0001193125-26-219678.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219678 | | 2026-05-12 | 20:17 ET | [8-K](/filings/0001193125-26-219507.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219507 | | 2026-04-27 | 20:45 ET | [DEF 14A](/filings/0001193125-26-182293.md) | Proxy statement, period 2026-06-18 | 0001193125-26-182293 | | 2026-03-05 | 21:50 ET | [10-K](/filings/0001193125-26-094159.md) | Annual report, period 2025-12-31 | 0001193125-26-094159 | | 2026-03-05 | 21:11 ET | [8-K](/filings/0001193125-26-093961.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093961 | | 2026-01-08 | 14:05 ET | [8-K](/filings/0001193125-26-007081.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-007081 | | 2025-11-12 | 21:45 ET | [10-Q](/filings/0001193125-25-277815.md) | Quarterly report, period 2025-09-30 | 0001193125-25-277815 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-094159.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1593899 - Tickers: AVIR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: MA - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.